Given the findings regarding SGLT2i and GLP-1 Ras in DM and sarcopenia, their use in clinical practice might be considered in addition to the already known cardiorenal benefits currently recognized in clinical guidelines. The gene discussed is GLP1R; the disease is sarcopenia.